Diamyd® subcutaneously continues to show weaker results than when administered intralymphatically
A preliminary 15-month interim report from EDCR IIa, an investigator initiated pilot trial where the diabetes vaccine Diamyd® is administered subcutaneously in combination with etanercept and vitamin D shows, when all 20 patients have been followed for fifteen months, that the treatment is safe and tolerable. No serious side effects have been reported. Results pertaining to the patients’ own insulin production, HbA1c and external insulin requirements are, however, weaker in EDCR IIa than from the ongoing DIAGNODE-1 trial where the diabetes vaccine is administered directly into the lymphnode.
